Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Cancer ; 150(4): 562-571, 2022 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-34558660

RESUMEN

Whether regular fish oil supplementation is associated with cancer risk is controversial. We aimed to evaluate the association of fish oil supplementation on cancer risk according to fatty fish consumption patterns. From the UK Biobank cohort, 470 804 participants with fish oil supplementation data were included. A total of 147 316 individuals with fish oil supplementation were in the exposed group; the other 323 488 were in the unexposed group. No association was found between self-report regular fish oil supplementation and overall cancer risk (hazard ratio [HR] = 0.97, 95% confidence intervals [CIs] = 0.95-1). Stratified by fatty fish consumption level, we found the association between fish oil supplementation and lower cancer risk in participants who consumed fatty fish less than two times per week, with association noted for both overall cancer (HR = 0.96, 95% CI = 0.94-0.99) and some specific cancers (colon cancer: HR = 0.84, 95% CI = 0.75-0.94; hepatobiliary cancer: HR = 0.74, 95% CI = 0.58-0.96; lung cancer: HR = 0.87, 95% CI = 0.78-0.98). On the contrary, a higher risk of breast cancer was observed (HR = 1.16, 95% CI = 1.01-1.32) in participants who consumed fatty fish at least two times per week. In conclusion, our findings underscore the need to refine recommendations for nutritional supplements according to inherent diet habits.


Asunto(s)
Suplementos Dietéticos , Aceites de Pescado/administración & dosificación , Neoplasias/etiología , Adulto , Anciano , Conducta Alimentaria , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Alimentos Marinos
2.
Pak J Pharm Sci ; 31(4(Special)): 1713-1717, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30203768

RESUMEN

The treatment of influenza A (H1N1) is mainly antiviral treatment, symptomatic treatment or traditional Chinese medicine treatment. Previous studies showed that the extract of Bupleurum has the functions of anti-inflammatory, antiviral, regulating the immune system and so on, which can be used to treat influenza. In this paper, we analyze the drug effect of bupleurum compound medicine, at the same time, using oseltamivir as control group. The results showed that the Chinese medicine chima qingwen decoction had certain antiviral effects. No adverse reactions occurred during the treatment period, and the overall effective rate was 93.3%. It shows that combination therapy of Chinese and Western medicine is feasible for mild cases of influenza A (H1N1). Therefore, the research and development of Chinese medicine preparations has positive research significance and sufficient market potential.


Asunto(s)
Bupleurum/química , Medicamentos Herbarios Chinos/uso terapéutico , Gripe Humana/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antivirales/uso terapéutico , Medicamentos Herbarios Chinos/química , Femenino , Humanos , Subtipo H1N1 del Virus de la Influenza A/efectos de los fármacos , Masculino , Persona de Mediana Edad , Oseltamivir/uso terapéutico , Té/química , Adulto Joven
3.
Metallomics ; 7(3): 544-52, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25697676

RESUMEN

Chronic arsenic exposure through drinking water threatens public health worldwide. Although its multiorgan toxicity has been reported, the impact of chronic arsenic exposure on the metabolic network remains obscure. In this study, male Sprague Dawley rats were exposed to 0.5, 2 or 10 ppm sodium arsenite for three months. An ultra-high performance liquid chromatography/mass spectrometry based metabolomics approach was utilized to unveil the global metabolic response to chronic arsenic exposure in rats. Distinct serum metabolome profiles were found to be associated with the doses. Eighteen differential metabolites were identified, and most of them showed dose-dependent responses to arsenic exposure. Metabolic abnormalities mainly involved lipid metabolism and amino acid metabolism. The metabolic alterations were further confirmed by hepatic gene expression. Expressions of cpt2, lcat, cact, crot and mtr were significantly elevated in high dose groups. This study provides novel evidence to support the association between arsenic exposure and metabolic disruption, and it contributes to understanding the mechanism of chronic arsenic toxicity.


Asunto(s)
Aminoácidos/metabolismo , Arsénico/toxicidad , Exposición a Riesgos Ambientales , Metabolismo de los Lípidos/efectos de los fármacos , Metabolómica , Pruebas de Toxicidad , Animales , Intoxicación por Arsénico/sangre , Intoxicación por Arsénico/metabolismo , Enfermedad Crónica , Análisis Discriminante , Regulación de la Expresión Génica/efectos de los fármacos , Homeostasis/efectos de los fármacos , Análisis de los Mínimos Cuadrados , Metabolismo de los Lípidos/genética , Masculino , Metaboloma/efectos de los fármacos , Análisis Multivariante , Análisis de Componente Principal , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas Sprague-Dawley , Reacción en Cadena en Tiempo Real de la Polimerasa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA